The stock climbed to $78.88, erasing previous losses to bring the company’s year-to-date performance to a flat position. During the trial, bitopertin demonstrated a statistically significant reduction in whole-blood metal-free protoporphyrin IX—the toxic byproduct responsible for the disease—compared to a placebo. Participants also reported a marked increase in their ability to spend time in sunlight without pain by the sixth month of the study.

Chief Executive John Quisel described the clinical data as an ideal outcome for the program. Disc Medicine is now preparing to engage with regulatory bodies to accelerate the drug's path to market. Further granular details from the study are expected to be presented at an upcoming medical conference, offering a clearer picture of the treatment's potential for those suffering from the condition's underlying heme biosynthesis mutations.